Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Xtant Medical Holdings (XTNT) Share-based Compensation (2016 - 2025)

Xtant Medical Holdings has reported Share-based Compensation over the past 16 years, most recently at $600000.0 for Q3 2025.

Quarterly Share-based Compensation fell 45.45% to $600000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2025, down 28.11% year-over-year, with the annual reading at $4.1 million for FY2024, 50.31% up from the prior year.
Share-based Compensation was $600000.0 for Q3 2025 at Xtant Medical Holdings, down from $800000.0 in the prior quarter.
Over five years, Share-based Compensation peaked at $1.2 million in Q2 2024 and troughed at $439000.0 in Q2 2023.
The 5-year median for Share-based Compensation is $641000.0 (2022), against an average of $715105.3.
Year-over-year, Share-based Compensation soared 173.35% in 2024 and then tumbled 45.45% in 2025.
A 5-year view of Share-based Compensation shows it stood at $708000.0 in 2021, then dropped by 9.75% to $639000.0 in 2022, then soared by 46.79% to $938000.0 in 2023, then decreased by 12.9% to $817000.0 in 2024, then fell by 26.56% to $600000.0 in 2025.
Per Business Quant, the three most recent readings for XTNT's Share-based Compensation are $600000.0 (Q3 2025), $800000.0 (Q2 2025), and $758000.0 (Q1 2025).